PAVM vs MGRX vs HIMS vs NVCR

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). PAVmed Inc. (PAVM) offers the better valuation at 14. 4x trailing P/E, making it the more compelling value choice. Analysts rate PAVmed Inc. (PAVM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PAVmed Inc.

(PAVM) is the cheapest at 14. 4x versus Hims & Hers Health, Inc. at 50. 3x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mangoceuticals, Inc.

(MGRX) is the lower-risk stock at 0. 90β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 166% more volatile than MGRX relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: PAVmed Inc. grew EPS 105. 4% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, PAVM leads at 81. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PAVmed Inc.

(PAVM) is the more profitable company, earning 1329% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 1329% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -1485. 4% for PAVM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, MGRX (100.

0% yield) pays a dividend. PAVM, HIMS, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mangoceuticals, Inc.

(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 4%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAVM is a small-cap high-growth stock; MGRX is a small-cap income-oriented stock; HIMS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. MGRX pays a dividend while PAVM, HIMS, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.